Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of dutasteride on mood, HPA [hypothalamic-pituitary-adrenal] axis, and serum allopregnanolone levels in women with menstrual-related mood disorders and controls

Trial Profile

The effects of dutasteride on mood, HPA [hypothalamic-pituitary-adrenal] axis, and serum allopregnanolone levels in women with menstrual-related mood disorders and controls

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Premenstrual dysphoric disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Mar 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 09 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top